文献速递血管炎

司库奇尤单抗对托珠单抗治疗失败后的大细胞动脉炎患者有效且安全

Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该病例系列纳入意大利三中心六例托珠单抗治疗失败的大细胞动脉炎患者,启动司库奇尤单抗皮下注射(300 mg 每周一次共4周,随后300 mg 每月一次)。六个月内全部患者达到临床和实验室缓解,四例影像学确认活动性血管炎者影像学完全缓解,三例在四个月内成功停用糖皮质激素,未见不良事件。

要点

  • 六例托珠单抗失败的大细胞动脉炎患者接受司库奇尤单抗后六个月内全部达到临床和实验室缓解。
  • 四例基线影像学确认活动性血管炎者影像学确认血管炎完全缓解。
  • 三例在四个月内成功停用糖皮质激素,其余三例继续低剂量泼尼松(每日1.25、2.5、5 mg)。

核心结论

  • 司库奇尤单抗在托珠单抗治疗失败的大细胞动脉炎患者中有效实现临床和影像学缓解。
  • 这些初步真实世界发现支持IL-17A抑制在大细胞动脉炎管理中的潜在作用,尤其在IL-6阻断应答不足的病例中。
  • 需更大规模研究证实这些观察结果。

研究设计与样本

  • 研究为病例系列,纳入来自意大利三个中心的六例大细胞动脉炎患者,均在托珠单抗治疗失败后启动司库奇尤单抗。
  • 托珠单抗失败定义为疾病复发,表现为临床症状和/或影像学血管炎症。
  • 司库奇尤单抗皮下注射,300 mg 每周一次共4周,随后300 mg 每月一次。
  • 临床应答在六个月时评估,基于症状缓解和炎症标志物正常化;对既往记录复发的病例用影像学确认缓解。

主要发现

  • 队列全部为女性,中位年龄72岁(IQR,67-73)。
  • 疾病起病时所有患者均有颅部症状,四例有全身症状。
  • 托珠单抗失败发生于中位14个月(IQR,11-22)。
  • 启动司库奇尤单抗后,所有患者在六个月内达到临床和实验室缓解。
  • 四例在启动司库奇尤单抗前有记录活动性疾病者,影像学确认血管炎完全缓解。

局限性

  • 原文结论指出需更大规模研究证实这些观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effectiveness and safety of secukinumab in patients with GCA who experienced an inadequate response to tocilizumab. METHODS: This is a case series of six patients with GCA started on secukinumab after tocilizumab failure from three centres in Italy. Tocilizumab failure was defined as disease relapse, indicated by clinical symptoms and/or vascular inflammation on imaging. Secukinumab was administered subcutaneously at 300 mg weekly for 4 weeks, subsequently at 300 mg monthly. Clinical response was assessed at six months based on resolution of symptoms and normalization of inflammatory markers. Imaging was used to confirm remission in cases where it had previously documented relapse. RESULTS: The cohort consisted exclusively of women, with a median age of 72 years (IQR, 67-73). At disease onset, all patients had cranial symptoms, and four experienced constitutional symptoms. Tocilizumab failure occurred after a median of 14 months (IQR, 11-22). Following secukinumab initiation, all patients achieved clinical and laboratory remission within six months. Imaging confirmed complete resolution of vasculitis in the four patients with documented active disease before start of secukinumab. Three patients successfully discontinued glucocorticoids within four months, while the remaining three continued low-dose prednisone (1.25, 2.5, 5 mg daily). No adverse events were reported during secukinumab treatment. CONCLUSIONS: Secukinumab demonstrated effectiveness in achieving clinical and imaging remission in patients with GCA failing tocilizumab. These preliminary real-world findings support the potential role of IL-17A inhibition in GCA management, particularly in cases of inadequate response to IL-6 blockade. Larger studies are warranted to confirm these observations.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tomelleri A, Bond M, Marvisi C, et al. Secukinumab is effective and safe for patients with giant cell arteritis after tocilizumab failure. Rheumatology (Oxford). 2025. PMID: 40366735. doi:10.1093/rheumatology/keaf250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。